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Sumoylationoteins (C/EBPs) and peroxisome proliferator-activated receptors gamma (PPARG)
play critical roles in the regulation of lipid metabolism genes. Overexpression of CEBPdelta (CEBPD) enhances
lipid accumulation and speciﬁcally activates PPARG2 transcription in HepG2 cells. By using 5′-serial deletion
reporter analysis, we show that the region comprising the −457 to +129 base pairs is required for CEBPD
response of the PPARG2 promoter. Two critical CEBPD-binding motifs on the −324/−311 and −158/−145 of
human PPARG2 promoter are identiﬁed. We previously have shown that the human CEBPD is sumoylated by
small ubiquitin-related modiﬁer-1 (SUMO1). We further demonstrated that the sumoylation of CEBPD lysine
120 is also detectable in HepG2 cells, and this modiﬁcation functions for binding of the recruits, HDAC1 and
HDAC3. Meanwhile, an in vivo chromatin IP assay demonstrated that the sumoylation mutant of CEBPD lost a
signiﬁcant portion of HDAC1 and HDAC3 interaction. Combining that the increasing amount of CEBPD and
the sumoylated CEBPD (suCEBPD) consistently responded to lipogenic stimulation, these results suggest that
the excess non-sumoylated CEBPD could be a critical activator which reverses suCEBPD/HDAC1/HDAC3-
mediated PPARG2 gene inactivation and promotes hepatic lipogenesis. Taken together, we suggest that
suCEBPD/HDAC1/HDAC3 complex inactivates PPARG2 transcription, and the induction of CEBPD expression
transiently activates PPARG2 transcription which is involved in adipocyte-like lipogenesis in HepG2 cells.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionEukaryotic chromatin is dynamically modulated by post-translational
modiﬁcations of histones [1] to alter gene expression. Several recent
studies have shown that regulators of chromatin's structure are also
involved in adipocyte differentiation. Histone acetyltransferases (HATs)
and histone deacetylases (HDACs) have been shown to respond to signals
that regulate cell differentiation and directly modulate tissue-speciﬁc
gene expression. When preadipocytes are exposed to differentiation
conditions, a complex signaling cascade induces the expression of
previously silent adipogenic and lipogenic genes [2,3]. Downregulation
of HDACs was observed during adipocyte differentiation, especially in an
initiation status [4]. In 3T3-L1 cells, decreases in the expression levels of
severalHDACsor treatmentwith the inhibitorofHDACs, sodiumbutyrate,ction, College of Bioscience and
n 70101, Taiwan Tel.: +886 6
g).
l rights reserved.resulted in stimulation of adipogenic gene expression and adipocyte
differentiation [2]. Furthermore, the knockdown of HDAC1 promoted
adipogenesis whereas HDAC1 overexpression attenuated adipocyte
differentiation in 3T3-L1 cells [2]. Lipogenesis is one of the metabolic
pathways in adipogenesis. However, details of how these lipogenic genes
maintain quiescent and become activated in lipogenesis remain elusive. It
is reasonable to speculate that HDAC-mediated chromatin remodeling is
involved in the hepatic lipogenesis gene regulation.
Adipogenesis is dependent on the sequential activation of transcrip-
tion factors including C/EBPs, PPARG and steroid regulatory element-
binding protein (SREBP) [5,6]. PPARG is known as a critical regulator of
adipogenesis and a target of thiazolidinedione (TZD) antidiabetic drugs.
PPARG contains two major isoforms, PPARG1 and PPARG2, which are
encoded from a gene by alternative splicing, and the transcriptional
activations of PPARG1 and PPARG2 transcripts are regulated through
independent promoters [7]. PPARG2 is highly expressed in adipose tissue
and is upregulated in the steatotic liver of ob/obmice, whereas PPARG1 is
found at low levels in many tissues [8–10]. PPARG participates in the
transcriptional activation of a number of adipogenic transcription factors
and lipogenic genes, which are important for anti-inﬂammation,
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transport [11–17]. Increased expression of PPARG2 in hepatocytes results
in lipid accumulation and de novo lipid synthesis, which is suggested to
contribute to steatosis in hepatocytes [18]. Several transcription factors,
C/EBPs [19], GATAs and CREB [19], have been reported to regulate gene
expression of the two PPARG isoforms. However, the integration
mechanisms including how these factors inactivate and turn on
transcriptional activation combining transcriptional remodeling factors
and transcriptional modulators are still less studied, especially in the
human PPARG2 gene.
The C/EBP family includes six nuclear transcription factors, CEBPA,
CEBPB, CEBPG, CEBPD, CEBPE and CEBPZ. C/EBP family members can
form homo- or heterodimers to regulate gene transcription involving
the integrated metabolic processes ranging from the acute-phase
response to hepatic glucose homeostasis and adipose tissue differ-
entiation. Combined with their distribution across a variety of cell
types, it is difﬁcult to distinguish between unique and redundant
functions of transcription factors on gene expression. Both CEBPD and
PPARG2 show similarities in cells including (1) their distribution in
hepatocytes and adipocytes, (2) their ability to control lipogenesis and
differentiation of adipocytes and (3) they are induced and involved in
the regulation of cell growth arrest and apoptosis. CEBPD also
regulates several important adipogenic genes, such as adiponectin
[20], KLF15 [21] and CEBPA [22]. Therefore, it would be interesting to
address the CEBPD-mediated hepatic lipogenesis and the context. It is
known that tumor necrosis factor-α (TNF-α) represses mouse PPARG2
transcription through downregulating Cebpd in 3T3-L1 cells [23],
implying that the CEBPD potentially regulates PPARG2 transcription,
yet the detailed mechanism remains unclear. In addition, post-
translational modiﬁcations of transcription factors are important to
their accurately performing their biological functions [24,25]. We
previously reported that CEBPD can be modiﬁed by sumoylation or
acetylation and acts as a bifunctional regulator and modulate
cyclooxygenase (COX)-2 transcription [25]. We also suggested that
the ratio of non-sumoylated and sumoylated CEBPD could determine
the transcriptional activation of target genes. However, the participat-
ing components that interacted with suCEBPD and the target genes
that were transcriptionally regulated by suCEBPD complex are not
well characterized.
Previous research on adipogenesis and lipid metabolism has
mainly focused on investigating the regulatory roles of speciﬁc
transcription factors. However, the coordination of functional roles
between coregulators, such as HDACs, and speciﬁc lipogenic
transcription factors, such as CEBPD, during this processes is less
studied, especially in hepatic lipogenesis. Herein, we demonstrate
that induction of CEBPD can enhance hepatic lipogenesis and
activate PPARG2 transcription. suCEBPD binds to the PPARG2
promoter and interacts with HDAC1 and HDAC3 to attenuate
PPARG2 transcription. Increase of CEBPD competes against the
inactivation complex to activate PPARG2 transcription upon lipogenic
stimulation of cocktail, IBMX/dexamethasone/insulin (MDI). These
data suggest a novel evidence for the scenario of PPARG2 transcrip-
tion through the sumoylation of CEBPD and HDAC1/3 in hepatic
lipogenesis.
2. Materials and methods
2.1. Materials
Antibodies against CEBPD (sc-636), HDAC1 (sc-8410), HDAC2 (sc-
7899), HADC3 (sc-17795), HDAC4 (sc-11418), COX-1 (sc-1752), GAPDH
(sc-32233) and hemagglutinin (HA) (sc-7392), speciﬁc for immuno-
precipitation (IP) and chromatin IP, were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). An antibody against PPARG2 was
purchased from Abcam Biotechnology (Cambridge, UK). An antibody
against HA was purchased from BABCO (Richmond, CA). Antibodiesagainst FLAG and β-actin were purchased from Sigma (St. Louis, MO).
The TRIzol RNA extraction reagent, Lipofectamine 2000, Dulbecco's
modiﬁed Eagle's medium (DMEM), SuperScript™ III and Opti-MEM
medium were obtained from Invitrogen (Carlsbad, CA). All oligonu-
cleotides were synthesized by MDBio Inc. (Taipei, Taiwan). Fetal
bovine serum (FBS) was from HyClone Laboratories (Logan, UT). The
Luciferase assay system was purchased from Promega (Madison, WI).
The tet-off-inducible CEBPD expression vector, pTRE2-HA/CEBPD, was
generated by cloning CEBPD cDNA with BamHI and NheI into pTRE-
hyg vector. The zinc-inducible CEBPD expression vector, pMT-HA/
CEBPD, was constructed by cloning CEBPD cDNA with BamHI and
HindIII into the pMTCB6+ vector. The pMTCB6+ was a gift fromDr. Sigal
Gery (Cedars–Sinai Medical Center, Los Angeles, CA, USA).
2.2. Cell culture, treatments and Oil red O staining
A431, a human epidermoid carcinoma cell line, HepG2, a
hepatoblastoma cell line, Huh7, a hepatoma cells and 293T cells
were maintained in complete medium including DMEM supplemen-
ted with 10% FBS, 100 μg/ml streptomycin, and 100 units/ml penicillin
at 37 °C and 5% CO2. HepG2 cells were allowed to grow to around 60%
conﬂuence in complete medium and then were stimulated with
lipogenic cocktail, 0.5 mM IBMX, 10 μg/μl insulin and 1 μM
dexamethasone, for two days and then were maintained in complete
medium with 10 μg/μl insulin for an additional two or three days. For
the lipid synthetic assay by the Oil red O staining, two CEBPD-
inducible expression systems, a tet-off inducible system and a zinc-
inducible system, were performed in HepG2 or Huh7 cells. Brieﬂy, the
inducible vectors were transiently transfected into cells. For tet-off
inducible system, pTet-off vectors and pTRE2-HA/CEBPD expression
vectors were co-transfected into HepG2 cells. After transfection, the
CEBPD-tet-off transfectants were equally reseeded and grown in the
complete medium containing 2 μg/ml Doxycycline, 400 μg/ml G418
and 800 μg/ml hygromycin for 48 h. After PBS washing, the
transfectants were kept in tet-free complete medium for another
60 h for the Oil red O staining. For the zinc-inducible system, the
CEBPD-zinc-inducible transfectants were equally reseeded and grown
in the complete medium containing 100 μM ZnSO4 for 48 h for the Oil
red O staining. Oil red O staining followed a previously described
method [26].
2.3. Human PPARG2 promoter cloning and mutagenesis
The reporter bearing the PPARG2 promoter, −1800/+129, was a gift
from Dr. CW Chow (Department of Molecular Pharmacology, Albert
Einstein College of Medicine, NY, USA) [27]. 5′-Serial deletion mutants of
PPARG2 promoter were further generated by polymerase chain reaction
(PCR)with the following primers: PPARG2/−457SmaI: 5′-CAGTAGCATGCT-
GATACCAACG-3′, PPARG2/−304SmaI: 5′-TAAGTTTTCCATTTAAGAAGC-3′,
PPARG2/−130SmaI: 5′-CCAAGTCTTGCCAAAGCAGTG-3′ and PPARG2/
+129XhoI: 5′-GGCTCGAGATAGCATGGAA- TAGGGGTTTGCTGTAATTC-3′.
The PCR fragments were cloned into yTA vectors and veriﬁed by
sequencing. These veriﬁed fragments were digested with SmaI and XhoI
and thensubcloned into themulti-cloning sitesof thepromoter-lessvector,
pGL2-basic.Mutant reporter plasmidswere derived from −457/+129wt by
site-directedmutagenesis following the instructionsof theQuikChangSite-
directed Mutagenesis Kit (Stratagene, CA) with the M2 (5′-
GCTTTCTGGTATGTTAACAGCAAGAGATTTAAG-3′) or M3 (5′-GCGAGA-
CAGTGTGTTAACATTTTCCCTGTACC-3′) primers.
2.4. Plasmid transfection and reporter gene assay
To analyze the promoter activity of PPARG2 reporter genes, HepG2
cells were transiently transfected with these plasmids as indicated by
Lipofectamine 2000 according to the manufacturer's instructions. The
total DNA amount for each experiment was matched equally with
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transfectants in Opti-MEM were changed to complete medium and
incubated for further 15 h. Luciferase activities in cell lysates of
transfectants were measured by the Luciferase Assay System accord-
ing to the manufacturer's instructions. For the dominant negative
CEBPD expression vector (CEBPDDN), the NotI/Klenow/SalI fragment
of CEBPD cDNA was inserted into the pCDNA3/HA vector by BamHI/
Klenow/SalI. It results in an N-terminal deletion mutant, lacking 1–
150 amino acids, of CEBPD expression vector.
2.5. Reverse transcription-PCR (RT-PCR)
Total RNA was isolated from cells using the TRIzol RNA extraction
reagent. Twomicrograms of the isolated RNAwas subjected to reverse
transcription with SuperScript™ III. Speciﬁc primers for PPARG2: 5′-
GCGATTCCTTCACTGATAC-3′ and 5′-GCATTATGAGACATCCCCAC-3′;
PPARG1: 5′-CGGGATCCGTTGACACAGAGATGCCATT-3′ and 5′-CATCAT-
TAAGGAATTCATGTC-3′; CEBPD: 5′-AGCGCAACAACATCGCCGTG-3′
and 5′-GTCGGGTCTGAGGTATGGGTC-3′ and β-actin: 5′-CCCAAGGC-
CAACCGCGAGAAG-3′ and 5′-TCTTCATTGTGCTGGGTGCCA-3′ were
used for the analyses. The PCR products were separated by electro-
phoresis in 1% agarose gels and visualized with ethidium bromide
staining.
2.6. Western blot analysis and immunoprecipitation assay
Cells were lysed in modiﬁed RIPA buffer [25] for Western blotting.
Following lysis, lysates were resolved on a sodium dodecylsulfate
(SDS)-containing 10% polyacrylamide gel, transferred to polyvinyli-
dene diﬂuoride (PVDF) nylon membrane, and probed with speciﬁc
antibodies at 4 °C overnight. Speciﬁc bands were detected by a
horseradish peroxidase-conjugated antibody and revealed by an
enhanced chemiluminescence (ECL) Western blot system from Pierce
(Rockford, IL). An in vivo-sumoylation assay was carried out in HepG2
cells. Cells were transfected with the pcDNA3-HA/CEBPD or pcDNA3-
HA/CEBPDK120A expression vectors for 20 h. Cell extracts were
prepared as previously described [25]. For the immunoprecipitation
assay, the transfectants were lysed by a freeze-thawing method in the
buffer containing 20 mMHEPES (pH7.9), 0.1 mM EDTA, 1.5 mMMgCl2,
1 mM DTT and 50 mMNaCl. One microgram of antibodies recognizing
the HA-tag was incubated with 200 μg of lysates at 4 °C overnight for
the immunoprecipitation. The immune complex was washed twice
with washing buffer containing 1×PBS with 0.5% NP-40 then
separated by 10% SDS-polyacrylamide gel electrophoresis (PAGE) for
Western blotting with the indicated antibodies.
2.7. Small interfering RNA (siRNA) and short hairpin RNA (shRNA) assay
The knockdown HDAC1 and HDAC3 expression vectors were
purchased from the national RNAi (interfering) core facility of
Academia Sinica, Taipei, Taiwan. The targeting sequences of HDAC1:
5′-CCGCAAGAACTCTTCCAACTT-3′ and HDAC3 5′-GTACCTATTA-
GGGATGGAGAT-3′ were inserted in pLKO.1 vector. For the siRNA
sequence of HDAC3 is 5′-GGGAGCCCACGAGGTGTAACT-3′ [28]. The
siRNA against HDAC1, sc-29343, was purchased from Santa Cruz
Biotechnology. The knockdown CEBPD expression vector was as
previously described [25].
2.8. Gel shift assay
The 32P-labeled oligonucleotide probes (∼0.2 to 0.5 ng) containing
the individual putative C/EBP site were incubated with 1 μl of in vitro-
translated HA/CEBPD in speciﬁc binding buffer, as described below,
containing 1 μg of poly(dI-dC). After 20 min of incubation at room
temperature, the reaction mixtures were resolved in a 5% native
polyacrylamide gel (with an acrylamide/bisacrylamide ratio of 30:1) at4 °C, and the speciﬁc protein complexes were visualized by
autoradiography. The CRE binding buffer contained 10 mM Tris–HCl
(pH 7.5), 50 mMNaCl, 1 mM dithiothreitol (DTT), 1 mM EDTA, and 10%
(vol/vol) glycerol. For the antibody supershift experiments, 1 μg of
antibodies against CEBPD was included in the binding reaction
mixture. For the competitive experiments, a 20-fold molar excess of
unlabeled wild-type was included in the binding reaction mixture.
The sense strand sequences of various oligonucleotides used were site
1 (5′-GAAAACTTTGCCCAAGTAAGC-3′), site 2, (5′-CTGGTATTTCAT-
AAGCAAGAG-3′); site 3, (5′-GAGACAGTGTGGCAATATTT-3′) and site
4, (5′-ACCAAGTCTTGCCAGAGCAG-3′).
2.9. DNA afﬁnity precipitation assay (DAPA)
Sumoylated in vitro-translated HA/CEBPD (IVT-HA/CEBPD) was
prepared with a sumoylation kit as previously described [25]. Nuclear
extracts from A431 cells were prepared, and a DNA afﬁnity precipita-
tion assay was performed according to a previously described method
[25]. Brieﬂy, 200 μg of nuclear extracts was incubated with 1 μg of
biotinylated oligonucleotides, C/EBP or CRE motifs of the COX-2
promoter (Nucleic Acids Res 34 (2006) 217–231), preincubated with
equal amounts of sumoylated or non-sumoylated IVT-HA/CEBPD in
the presence of DNA-binding buffer containing 10 mM Tris–HCl (pH
7.5), 50 mM NaCl, 1 mM DTT, 1 mM EDTA, 10% (v/v) glycerol, 10 mM
NaF, 1 mM PMSF, 1 μg aprotinin/ml, 1 μg leupeptin/ml, 1 mM Na3VO4
and 2 μg poly(dI-dC). After 1 h of incubation at 4 °C, 40 μl of
streptavidin-magnetic beads was added to the reaction mixture, and
the incubation was continued for 1 h. The complexes were then
precipitated by centrifugation and washed three times with DNA-
binding buffer before being resolved by SDS-PAGE and subsequently
analyzed by immunoblotting with antibodies recognizing HDAC1,
HDAC2 and HDAC3. For the determination of HDAC1- and HDAC3-
binding activity on the C/EBP site 2 or site 3 of PPARG2 promoter, the
HA/CEBPD or HA/CEBPDK120A expression vectors were transfected
into HepG2 cell. After 15 h recovering, the lysates of transfectants
were harvested for the DAPA. The binding and washing condition is
described above.
2.10. Chromatin immunoprecipitation (ChIP) and re-ChIP assays
The ChIP assay was carried out essentially as described byWang et al.
[29]. Brieﬂy, HepG2 cells were treated with 1% formaldehyde for 15 min.
The cross-linked chromatin was then prepared and sonicated to an
average size of 500 bp. The DNA fragments were immunoprecipitated
with antibodies speciﬁc for HDAC1, HDAC3, SUMO1 or C/EBPD, or control
rabbit immunoglobulin G (IgG) at 4 °C overnight. After reversal of the
cross-linking, the immunoprecipitated chromatin was ampliﬁed by
primers related to the speciﬁc regions of the PPARG2 genomic locus. For
the re-ChIP assay, the ﬁrst immune complex that had beenwashed twice
withwashing buffer, including 50mMTris–HCl pH8.0, 0.1% SDS, 0.5%NP-
40, 150 mM NaCl and 2.5 mM EDTA, and 3 times with low-salt buffer,
including 10 mM Tris–HCl (pH8.0) and 0.1 mM EDTA, was resolved in
10 mM DTT at 37 °C, further diluted in ChIP dilution buffer, and then
processed according to the same ChIP assay protocol using the indicated
antibodies. The primers were F-600(S) (5′-CAGTAGCATGCTGATAC-
CAACG-3′) and R-160(AS) (5′-CAGTTTCCAAATATTTGGGAGAGATGG-3′).
The ampliﬁedDNAproductswere resolved byagarose gel electrophoresis
and conﬁrmed by sequencing.
3. Results
3.1. CEBPD is involved in the regulation of hepatic lipogenesis
It has been demonstrated that CEBPD induces adipocyte-speciﬁc
genes and promotes adipocytic differentiation that has been demon-
strated in preadipocytes such as 3T3-L1 cells, when they are exposed
Fig.1. CEBPD participates in hepatic lipogenesis. (A, B) Overexpressed CEBPD induces hepatic lipogenesis. The transient overexpression of CEBPD in two CEBPD-inducible systemswas
performed in HepG2 or Huh7 cells. They were transiently expressed in HepG2 or Huh7 cells by treating them with or without Doxycycline or ZnSO4 as described in “Materials and
methods”. Oil red O dye in (A) was extracted by isopropanol and quantitated at O.D. 510 nm. Relative values were normalized to the control. (C) Treatment of lipogenic stimulation
increases lipid accumulation and expression of the lipogenic gene, PPARG2. HepG2 cells at 60% conﬂuency were exposed to MDI treatment for 48 h and then the culture mediumwas
changed to insulin for 2 (right panel) or 3 (left panel) days. Representative photographs of the cells stained with Oil red O are shown (200×and 400× magniﬁcations) (left panel). On
day 2, whole cell lysates were prepared and analyzed by Western blotting with the antibodies as indicated (right panel).
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hepatoblastoma-derived cell line, HepG2, has become an accepted
model for studying lipoprotein metabolism in human hepatocytes.
Therefore, the issue of whether CEBPD is involved in regulating
hepatic lipogenesis was addressed by a gain-of-function assay.
Induction of CEBPD expression led to lipid accumulation in HepG2
cells (Fig. 1A and B). Moreover, this CEBPD-induced lipogenesis was
conﬁrmed in another hepatoma cells, Huh7 (Fig. 1B). CEBPD was
thought to regulate PPARG2 transcription [23,32]. However, the
detailed mechanism of transcriptional regulation including the
involvement of chromatin remodeling enzymes, for example HDACs,
is uncertain. To mimic lipid accumulation and clarify the scenario
between the adipogenic transcription factors and the chromatinremodeling enzymes, HepG2 cells were treated following the
adipocyte differentiation protocol described in “Materials and meth-
ods”. The lipogenic stimulation-induced lipogenesis in hepatic cells
was analyzed by Oil Red O staining (Fig. 1C, left panel). Meanwhile, the
protein lysates were harvested for the detection of CEBPD, PPARG2
and HDACs. Increased expressions of CEBPD, PPARG2, HDAC1 and
HDAC3 were observed after MDI treatment. However, HDAC4 showed
a decreasing pattern in this study (Fig. 1C, right panel).
3.2. CEBPD is involved in the expression of human PPARG2 gene
CEBPD is known to be activated by lipogenic stimulation and
functions in the early stage of adipogenesis in 3T3-L1 cells [33]. The
Fig. 2. CEBPD activates PPARG2 gene expression and promoter activity. (A) Overexpressed CEBPD increases endogenous PPARG2 gene expression. HepG2 cells were transfected with
CEBPD expression vectors. After 24 h, total RNAs or whole cell lysates were harvested to perform the RT-PCR or Western blotting. (B, C) Overexpression of CEBPD activates PPARG2
promoter activity. HepG2 cells were co-transfectedwith the PPARG2-457 (Fig. 3A) and expression vectors of CEBPD or CEBPDDN. After 24 h, cell lysates of transfectants were prepared
for the luciferase assay. (D) Silencing of CEBPD negatively regulates PPARG2 promoter activity. The PPARG2 reporter, PPARG2-WT (Fig. 3A), and CEBPD expression vectors were co-
transfected with the knockdown expression vectors of SiControl or SiCEBPD in HepG2 cells. After 24 h, cell lysates were prepared for the luciferase assay (left panel). The silencing
effect of exogenously expressed CEBPD was evaluated by Western blotting (right panel).
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activate CEBPD and PPARG2 in HepG2 cells. To verify whether CEBPD
activated PPARG gene in hepatocytes, a RT-PCR assay was performed by
the transfectants of transiently overexpressed or non-overexpressed
CEBPD. The results showed that overexpressed CEBPD speciﬁcally
increases PPARG2 transcription and protein (Fig. 2A), but not PPARG1
expression (data not shown). To further conﬁrm whether the CEBPD-
regulated PPARG2 expression occurs through promoter regulation, a
reporter assay was performed by co-transfection of PPARG2-wt reporter
with control or CEBPD expression vectors. Overexpressed CEBPD
enhanced PPARG2 promoter activity in a dose-dependent manner (Fig.
2B), and this CEBPD-induced reporter activity was attenuated by the
CEBPD dominant negative mutant, which lacks the N-terminal transac-
tivation domain (Fig. 2C). Meanwhile, a loss-of-function assay was
performed to reconﬁrm the CEBPD-mediated PPARG2 promoter regula-
tion by the co-transfection of CEBPD expression vectors and PPARG2
reporter with the silencing expression vectors of CEBPD or control.
Comparingwith thecontrol vector, theco-transfectionof speciﬁcCEBPD-
knockdown expression vector attenuates CEBPD-induced PPARG2
prompter promoter activity as shown in Fig. 2D. These data suggest
that the induction of CEBPD can be an activator for upregulating PPARG2
transcription through its promoter.
3.3. Two critical CEBPD-responsive motifs of the PPARG2 promoter are
identiﬁed
Although CEBPD was implied to be involved in regulation of the
PPARG2 promoter [23], the precise CEBPD-responsive motifs of
human PPARG2 promoter are uncertain. To clarify this issue, thevarious reporters bearing 5′-serial deletion mutants of PPARG2
promoter (Fig. 3A) were co-transfected with CEBPD expression vectors
to determine the CEBPD-responsive element ﬁrst. As shown in Fig. 3B,
overexpressed CEBPD signiﬁcantly activated the promoter activity of
PPARG2-1800 and PPARG2-457 by a 20-fold increase, but it was
reduced to 10- and one-fold, respectively, in co-transfectants of the
PPARG2-304 and PPARG2-130 reporters. This suggests that the region
of −457/−130 bp on PPARG2 promoter contains at least two CEBPD-
responsive elements. The promoter of mouse Pparg2 gene contains
two characterized C/EBP-binding sites during −345/−302 bp region
[23]. By comparing the proximal region sequence of human PPARG2,
−388/+134, and mouse Pparg2 promoter, −454/+67, 90% homology
was observed for these two promoters. There are four putative C/EBP
sites, site 1, 2, 3 and 4, on the PPARG2 promoter that are identiﬁed by
the prediction program of TFSEARCH website (http://www.cbrc.jp/
research/db/TFSEARCH.html). In order to dissect which C/EBP site
contains CEBPD-binding activity, an in vitro gel-shift assay was
performed. The in vitro-translated HA/CEBPD strongly interacted
with motifs of site 2 and site 3 but was only slightly bound to site 1
and site 4 (Fig. 3C). Meanwhile, the speciﬁc CEBPD antibody and excess
amounts of individual C/EBP oligonucleotides were recruited in this
assay to demonstrate speciﬁc CEBPD-binding activities. To further
determine whether site 2 and site 3 play critical roles in CEBPD-
mediated PPARG2 promoter regulation, three individual mutant
reporters of PPARG2-457 containing mutation of site 2 (M2), site 3
(M3) or both sites 2 and 3 (M2+M3) were generated by site-directed
mutagenesis (Fig. 3D, upper panel). In comparison with PPARG2-475,
M2 and M3 reporters partially lost the CEBPD inducibility (Fig. 3D,
lower panel). However, the PPARG2-475 reporter bearing double
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induced PPARG2 reporter ability. This suggests that both the C/EBP
motifs, site 2 and site 3, play essential roles in the CEBPD-regulated
PPARG2 transcription.3.4. suCEBPD has a higher afﬁnity to interact with HDAC1 and HDAC3
Proteinsmust be tightly regulated to execute their functional roles in
a cell. We previously identiﬁed the ﬁrst suCEBPD-regulated target gene,
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inactivates COX-2 transcription [25]. However, the detailed molecular
mechanism of suCEBPD-mediated gene inactivation is uncertain. To
elucidate how the suCEBPDplays a repressive role inmodulating PPARG2
gene transcription, the issue of whether CEBPD can be sumoylated in
HepG2 cells was addressed ﬁrst. Consistent with our previous study,
CEBPD could be sumoylated through the residue of lysine 120 in HepG2
cells (Fig. 4A). Lipogenic stimulation can induce HepG2 cells to change
toward adipocyte-like cells [34]. SUMO modiﬁcation regulates the
activity of numerous transcription factors that have been implied to
have several cellular functions, but its role in the enhancement of
lipogenesis processes is unknown, especially in suCEBPD-mediated gene
transcription. Whether the activity of sumoylation enzymes that
sumoylate CEBPD varies depending on the induction of lipogenic
stimulator could be important for clarifying theCEBPD-mediatedhepatic
lipogenesis. Therefore, the lysates of the exogenous expression of HA/
CEBPD upon MDI treatment were harvested to determine the sumoyla-
tion effect. It showed that the level of suCEBPD sustains constantly
regardless MDI treatment (Fig. 4B). HDACs were reported to be
chromatin remodeling regulators and involved in the sumoylated
transcription factor-mediated repression [35]. Our previous study
showed that suCEBPD can modulate COX-2 transcription through the
CRE andC/EBPmotifs. To screenpossibleHDACs for suCEBPD interaction,
a DAPA was performed by the preincubated protein–DNA complexes of
suCEBPD-C/EBP or suCEBPD-CRE with the nuclear extract of A431 cells.
suCEBPD exhibited higher binding afﬁnities with HDAC1 andHDAC3 but
not with HDAC2 (Fig. 4C). Moreover, this interactive activity was further
conﬁrmedbyco-immunoprecipitationwith thenuclearextract ofHepG2
cells to demonstrate this common phenomenon. HDAC1 and HDAC3
havehigher interaction activitieswith CEBPDwt, containing sumoylation
activity, but not CEBPDK120A mutant, which had lost its sumoylation
activity (Fig. 4D). To further investigate whether HDAC1 and HDAC3 can
be recruited by the suCEBPD to bind to the C/EBP site 2 and site 3 of
PPARG2 promoter, a DAPA experiment was performed. As shown in Fig.
4E, HA/CEBPD andHA/CEBPDK120A equally bound to C/EBP site 2 and C/
EBP site 3. However, HDAC1 and HDAC3 demonstrate a higher
interaction activity in the recruits of wild-type CEBPD but not
sumoylation mutant, CEBPDK120A, through C/EBP site 2 or C/EBP site
3. These data suggest that HDAC1andHDAC3 could be recruited onto the
C/EBP site 2 and C/EBP site 3 of PPARG2 promoter through suCEBPD.
3.5. CEBPD Lys 120 is important for HDAC1's and HDAC3's repression on
PPARG2 promoter activity
Overexpressed HDAC1 [36] and HDAC3 [37] or inhibition of HDAC
activities can modulate adipogenesis [2]. Meanwhile, PPARG2 plays a
critical role in hepatic lipogenesis [38]. To further elucidate the function
of HDAC1 and HDAC3 in the CEBPD-regulated PPARG2 transcription,
whether HDAC1 and HDAC3 are involved in the repression of PPARG2
transcriptionwas veriﬁed ﬁrst by RT-PCR analysis with siRNA of HDAC1
and HDAC3. Loss-of HDAC1 or HDAC3 increases PPARG2 transcripts in
HepG2 cells (Fig. 5A). Furthermore, whether CEBPD can function in
these HDAC1- and HDAC3-involved repressions on PPARG2 transcrip-
tion was veriﬁed. The PPARG2 reporter was co-transfected with CEBPD
expression vector and silencing expression vectors of HDAC1 or HDAC3
to address this issue. Silencing HDAC1 or HDAC3 expression enhancedFig. 3. The C/EBP-binding sites, sites 2 and 3, of the PPARG2 promoter are response to CEBPD
promoter used in this study. Site 1, site 2, site 3 and site 4 represent the putative C/EBP-bindin
element of PPARG2 promoter. Serial 5′-deletion constructs of the PPARG2 promoter were co-
transfectants were prepared for luciferase assay. (C) Site 2 and site 3 show strong CEBPD-bi
putative C/EBP motifs, site 1, site 2, site 3 and site 4, of PPARG2 promoter and in vitro-transla
the reaction mixtures as indicated lanes. For the competition analysis, the addition of a 20-fo
The “NS” arrow indicates the non-speciﬁc binding complex, the “S” arrow indicates the spe
antibody. (D) The C/EBP site 2 and site 3 of the PPARG2 promoter are important to respond
constructs of the PPARG2 promoter used in this study (upper panel). White boxes (dashed-d
CEBPD expression vectors and the wild-type or mutants of PPARG2 promoter as indicated. ACEBPD-regulated PPARG2 reporter activity (Fig. 5B), suggesting that the
wild-type CEBPD has the ability to respond to HDAC1- and HDAC3-
exerted suppressive effect. To investigate whether the sumoylation of
CEBPD can function in the repression of PPARG2 transcription, the
CEBPD and CEBPDK120A expression vectors were co-transfected with
the PPARG2-wt reporter to clarify this issue. Overexpression of
CEBPDK120A enhanced PPARG2 promoter activity, which suggests
that sumoylation of CEBPD indeed plays a negative role in the
regulation of PPARG2 transcription (Fig. 5C, compare lanes 2 and 6).
To further elucidate the involvement of HDAC1 andHDAC3 in suCEBPD-
regulated PPARG2 promoter activity, the exogenous expression vectors
of HDAC1, HDAC3 or HDAC2 were co-transfected with the expression
vectors of CEBPD and CEBPDK120A to address this issue. HDAC1 and
HDAC3, but not HDAC2, repressed CEBPD-activated PPARG2 promoter
activity (Fig. 5C, compare lane 2 with lanes 3 and 4), but this repressive
ability was lost in CEBPDK120A transfectants (Fig. 5A, compare lane 6
with lanes 7 and 8). Taken together, these data suggested that suCEBPD
functions as amodulator to participate inHDAC1- andHDAC3-inactived
PPARG2 transcription.
3.6. In vivo binding of the suCEBPD/HDAC1/HDAC3 complex on the
PPARG2 promoter
The results of the reporter assay showed that suCEBPD functions as
a repressor in transcriptional regulation of the PPARG2 gene. More-
over, a ChIP assay was performed to conﬁrm the in vivo binding
evidence of CEBPD on the PPARG2 promoter. The individual ChIP-PCR
products of Sumo1, CEBPD, HDAC1 and HDAC3 showed that they did
bind to the PPARG2 promoter region (Fig. 6B). To further determine
whether these proteins could form a complex on the PPARG2
promoter, a re-ChIP assay was performed. The results in Fig. 6C
demonstrate that Sumo1, CEBPD, HDAC1 and HDAC3 could form a
complex and bind to the PPARG2 promoter. The results of Fig. 5C
suggest that CEBPDK120A can enhance PPARG2 promoter activity. To
demonstrate if CEBPDK120A can attenuate the binding of HDAC1 or
HDAC3 onto PPARG2 promoter in vivo, the transient transfectants of
HA/CEBPDwt (HA-Wt) or HA/CEBPDK120A (HA-K120A) were ana-
lyzed by the ChIP and re-ChIP assays. The ChIP result showed that HA/
CEBPD and HA/CEBPDK120A retained the same DNA-binding activ-
ities (Fig. 6D, the middle panel). This is consistent with our previous
observation in an in vitro binding assay which suggested that the
sumoylation of CEBPD did not change its DNA-binding activity [25].
Furthermore, the re-ChIP results demonstrated that the mutant of
CEBPDK120A lost its ability to recruit HDAC1 and HDAC3, but not
HDAC2 (Fig. 6D, the lowest panel and the bottom ﬁgure of statistical
quantitative results). These in vivo results suggest that sumoylation-
modiﬁed CEBPD does play a functional role as a negative regulator
that mediates the HDAC1- and HDAC3-suppressive effects on PPARG2
promoter.
4. Discussion
Mouse 3T3-L1 cells are a well-studied system for adipogenesis. In
the mouse Pparg2 promoter, C/EBPs have been reported to act as
regulators in response to the TNF-α- or TGF-β-negative regulation
[23]. However, the transcriptional regulation of human PPARG2 gene isregulation. (A) Schematic representation of serial 5′-deletion constructs of the PPARG2
g sites on the proximal promoter of the PPARG2 gene. (B) Mapping the CEBPD-responsive
transfected with CEBPD expression vectors in HepG2 cells. After 24 h, the cell lysates of
nding activities. A gel-shift assay was performed with individual 32P-labeled probes of
ted HA/CEBPD. For the supershift assay, speciﬁc CEBPD antibodies were incubated with
ld molar excess of unlabeled C/EBP oligonucleotides was carried out as indicated lanes.
ciﬁc DNA–protein complex, and the “SS” arrow indicates the band supershifting by the
to CEBPD regulation. Schematic representation of single- and double-mutated reporter
otted line) indicate mutated C/EBP-binding sites. HepG2 cells were co-transfected with
fter 24 h, cell lysates of transfectants were prepared for luciferase assay (lower panel).
Fig. 4. Sumoylation of CEBPD increases the interactions with HDAC1 and HDAC3. (A) Sumoylated CEBPD, suHA/CEBPD, is detectable in HepG2 cells. The in vivo-sumoylation assay was
performed by transfection with pCDNA3-HA/CEBPD (HA/CEBPD) or pCDNA3-HA/CEBPDK120A (K120A). After 24 h, cell lysates were prepared for the Western blot analysis and
blotting with HA antibodies. (B) Sumoylation of CEBPD remains consistent in MDI-treated HepG2 cells. HepG2 cells were transfected with pCDNA3-HA or pCDNA3-HA/CEBPD
expression vectors. After 24 h of transfection, cells were treated with MDI for 2 days and then the cell lysates were harvested for Western blot analysis with HA antibodies. (C)
Sumoylated CEBPD has a higher afﬁnity to interact with HDAC1 and HDAC3, but not HDAC2. A DAPAwas performed by incubationwith nuclear extract of A431 cells and preincubated
complexes of CEBPD-binding oligonucleotides, C/EBPcox-2 or CREcox-2, and in vitro-sumoylated HA/CEBPD or native HA/CEBPD as described in “Materials and methods”. The in
vitro-sumoylation activity of HA/CEBPD is shown in the left panel. The reaction mixtures were separated by SDS-PAGE and blotted with indicated antibodies. “Wt” represents non-
sumoylated CEBPD; “Su” represents sumoylated CEBPD. The CEBPD-binding speciﬁcity of C/EBP or CRE oligonucleotides was performed by DAPA is shown in right-bottom panel. (D,
E) Non-sumoylated CEBPD attenuates HDAC1- and HDAC3-binding activities in HepG2 cells. Cells were transfected with pCDNA3-HA, pCDNA3-HA/CEBPD or K120A expression
vectors. After 24 h, cell lysates of transfectants were prepared and followed by the co-immunoprecipitation assay and DAPA as described in “Materials andmethods”. The precipitated
complexes were analyzed by Western blotting with indicated antibodies. Left panels of D show the quantitative results of three independent experiments by densitometer.
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transcription factors, such as liver X receptor, SREBP and CEBPB, have
been reported to involve in PPARG2 transcription upon lipogenic
stimulation. To reduce the effects of these transcription factors and
focus on CEBPD in PPARG2 transcription, we ﬁrst identiﬁed that
overexpression of CEBPD can enhance hepatic lipogenesis (Fig. 1A and
B) and PPARG2 transcription (Fig. 2) without lipogenic stimulation,and then we used this system to speciﬁcally dissect CEBPD-involved
PPARG2 transcription.
Comparing the sequences of the human PPARG2 promoter with the
mouse Pparg2 promoter, a high homology was observed between
their proximal promoters. We demonstrated that two of the four
putative C/EBP sites of PPARG2 promoter show high CEBPD-binding
activity and are involved in the CEBPD-mediated regulation (Fig. 3D).
Fig. 5. Lysine 120 of CEBPD is involved in HDAC1- and HDAC3-mediated repression of the PPARG2 promoter. (A) Attenuated HDAC1 and HDAC3 expressions reverse PPARG2 mRNA
level. Endogenous HDAC1 or HDAC3 were knocked down by transfection with siRNA of HDAC1 or HDAC3, respectively. Total RNAs were harvested from transfectants for RT-PCR
analysis. (B) Silence of HDAC1 or HDAC3 enhances CEBPD-induced PPARG2 promoter activity. The reporter vector of PPARG2-WT and the expression vector of pCDNA3-HA/CEBPD
were co-transfected with indicated knockdown expression vectors, including shHDAC1, shHDAC3 and shGFP, in HepG2 cells. After 24 h, cell lysates were prepared for luciferase assay.
The silencing effects of shHDAC1 and shHDAC3 are shown in the lower panel. C, The pLKO.1-shC control vector; shHDAC1 and shHDAC3, the pLK0.1-shHDAC1 and pLK0.1-shHDAC3
vectors, respectively. (C) CEBPDK120A attenuates HDAC1- and HDAC3-mediated repression of the PPARG2 promoter. HepG2 cells were co-transfected with PPARG2-WT and various
expression vectors as indicated. After 24 h, cell lysates of transfectants were harvested for luciferase assay.
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reported C/EBP sites of mouse Pparg2 promoter [7]. Recent studies
have shown that liver regeneration is impaired in a number of animal
models of fatty liver disease [39–41]. Rosiglitazone impairs mouse
liver regeneration with efﬁcacy corresponding to their relative
potencies against PPARG. Therefore, homeostatic regulation of hepatic
PPARG activity might be essential for normal liver regeneration and
also to control the hepatic lipogenesis. The combination of increased
CEBPD and PPARG2 expressions had the same effects in induction of
growth arrest and apoptosis (Supplementary Fig. 1, [42]), suggesting
that appropriate and accurate expression of CEBPD is important to
modulate PPARG2 to reverse or balance liver function.
The architecture of chromatin has a fundamental role in regulating
gene transcription in vivo. Through the regulation of chromatin
remodeling enzymes, histones and lipogenic transcription factors
were reported to regulate adipogenesis and lipogenesis. However, a
precise lipogenesis scenario needs to accurately integrate histone
modiﬁers and speciﬁc lipogenic transcription factors in cells. There-
fore, it has become important to clarify the details among these
factors. The relationship between CEBPD and chromatin remodeling
enzymes has not been previously studied. We demonstrate that
CEBPD incorporates with HDAC1 and HDAC3 (Figs. 4–6) to involve in
the transcription of the critical lipogenic factor, PPARG2. CEBPD can
form heterodimer with C/EBP family members [43] to coordinatelyregulate gene transcription and is thought to participate in adipogen-
esis [44]. Furthermore, this current study demonstrates that CEBPD
plays a functional role in lipogenic process of hepatic cell lines.
Therefore a global analysis clarifying the lipogenic genes, except
PPARG2, under regulation of the suCEBPD/HDAC1/HDAC3 complex
needs to be further characterized. HDAC3 is a member of class I
histone deacetylases [45–48]. It has activities that clearly distinguish
itself from other class I histone deacetylases, HDAC1 and 2 [49].
Interestingly, our results show that suCEBPD speciﬁcally modulates
the HDAC1- and HDAC3-exerted repression on PPARG2 gene regula-
tion. This suggests that suCEBPD has the potential to function as a
linker between these two HDACs in the nucleus. suCEBPD possesses
higher interactive activities with HDAC1 and HDAC3 but not with
HDAC2 (Fig. 4C). In addition, our preliminary data showed that HDAC4
has the same effect of favoring interaction with suCEBPD (Ju-Ming
Wang, unpublished results). Moreover, the re-ChIP assay demon-
strated that HDAC3 and HDAC1 are responsible for suCEBPD
interaction on the PPARG2 promoter without lipogenic stimulation
(Fig. 6D). This provides evidence to elucidate the reason why the
knockdown of HDAC1 and -3 can induce adipogenic progress [2,50].
Our results indicated that the HDAC3 and HDAC1 are speciﬁc cofactors
for CEBPD activity and participates in PPARG2 transcription in
hepatocyte. This ﬁnding also excludes the participation of HDAC2 in
some portion of CEBPD-modulated gene regulation, such as PPARG2
Fig. 6.HDAC1 and HDAC3 formed a complex with sumoylated CEBPD on the PPARG2 promoter in vivo. (A) The scheme of the 5′-ﬂanking region of the PPARG2 gene and the location of
designed primers for PCR. (B, C) SUMO1-conjugated proteins, CEBPD, HDAC1 and HDAC3 bind to the PPARG2 promoter in vivo. The ChIP and re-ChIP analyses were performed as
described in “Materials and methods”. Chromatins were separately immunoprecipitated with speciﬁc antibodies including control IgG, CEBPD, SUMO1, HDAC1 and HDAC3, and then
ampliﬁed by PCR with primers as indicated in (A). NC, the IgG control; D, the CEBPD antibody; SU1, the SUMO1 antibody; HD1, the HDAC1 antibody; HD3, the HDAC3 antibody. (D)
CEBPDK120A loses the ability to recruit HDAC1 and HDAC3 onto PPARG2 promoter, but not HDAC2. HepG2 cells were co-transfected with pCDNA3-HA, pCDNA3-HA/CEBPD or K120A
expression vectors. The extracted lysates of transfectants were prepared for Western blotting, ChIP assay and re-ChIP assay. The upper panel shows that equal amounts of HA/CEBPD
and HA/CEBPDK120A were expressed in the transfectants. The ChIP and re-ChIP assays were performed with α-HA antibodies, and the results are represented in middle and lower
panels. Consistent results were observed from at least 2 independent transfection experiments and the relative amounts of PCR products were plotted by normalizing and
designating the densities of the ampliﬁed HA/CEBPD immunoprecipitated products as 100%.
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increased in HepG2 cells after lipogenic stimulation (Fig. 1C).
Interestingly, this observation of HDAC1- and HDAC3-increase upon
lipogenic stimulation is different with observation in 3T3-L1 [2]. In
addition, the signiﬁcant induction of CEBPD was observed upon
lipogenic stimulation, but the amount of sumo-conjugated CEBPD
remained consistent in this stimulation (Fig. 4B). Taken together, these
data suggest that the ratio of suCEBPD/CEBPD plays an important role
to determine the PPARG2 transcription, but not the induction of
HDAC1 and HDAC3 in transcriptional activation of PPARG2 gene.
The functions of PPARG1 and PPARG2 are almost identical except
for only 28 amino acid difference in their N-terminus. PPARG1 and
PPARG2 are not only translated from differential splice variants but
also transcripted from different transcriptional initiation sites through
separate promoter regions [7]. Moreover, PPARG1 is expressed in a
variety of tissues at a relatively lower level, while PPARG2 is highly
expressed in adipocytes at the RNA level [15]. This observation also
suggests that PPARG1 and PPARG2 can be regulated from different
manners. In addition, CEBPD can interact with the retinoblastoma (RB)
protein [51,52] which implies that it might be a regulator of the cell
cycle. The RB protein has been shown previously to coordinate with
HDAC3 and facilitate adipocyte differentiation by inducing cell cycle
arrest. However, the RB lacks a DNA-binding domain and needs torecruit RB by a direct DNA-binding protein, for example E2F1.
Combining previous studies and our results suggests that the RB
protein and HDAC1/HDAC3, at least in part, can participate together to
involve in modulation PPARG2 transcription by CEBPD. Furthermore,
Rb can directly interact with CEBPA or CEBPB [51]. However, Rb-
mediated PPARG2 transcription cannot be regulated by overexpressed
CEBPA or CEBPB [53]. Our preliminary data shows that Rb can repress
CEBPD-induced PPARG2 transcription (Ju-Ming Wang unpublished
results). It suggests that CEBPD can be a good candidate to characterize
the Rb-regulated PPARG2 transcription.
CEBPD is thought to be a potential tumor suppressor [54]. As
mentioned above, the interaction between CEBPD and RB might
regulate adipogenesis-like phenomena as well as function in regulat-
ing differentiation. Furthermore, our preliminary results of the foci
formation assay demonstrated that overexpression of CEBPDK120A
shows a signiﬁcant inhibition activity against cell proliferation
compared to the wild-type CEBPD (Supplementary Fig. 1). This
suggests that CEBPDK120A can possibly be applied as a more-efﬁcient
tumor therapeutic agent than the wild-type CEBPD. In addition to
regulating the PPARG2 gene, CEBPD also regulates CEBPA transcription
in adipogenesis [22]. PPARG2 and CEBPA were recently reported to
induce hepatic hepatitis and ﬁbrosis [55–58]. Although the result of
overexpression of CEBPD and PPARG2 can induce cell arrest and
1813P.-H. Lai et al. / Biochimica et Biophysica Acta 1783 (2008) 1803–1814apoptosis that is also consistent with previous reporters, they are also
reported to be silenced in several tumors. Combining our preliminary
results, the overexpression of SUZ12/EZH2/DNMTs can result in
hypermethylation of the CEBPD promoter which attenuates its
expression in hepatocellular carcinoma and cervical cancer (Ju-Ming
Wang unpublished results). Taken together, it is speculated that the
increase of CEBPD enhances expressions of PPARG2 and CEBPA, which
not only function in the hepatic lipogenesis but also in the hepatic
hepatitis and cirrhosis. However the aberrant overexpression of E2F1-
medidated SUZ12/EZH2 attenuated the inducibility of the mitogen- or
inﬂammation-induced CEBPD gene expression in tumorigenesis (Ju-
Ming Wang unpublished results). This suggests that the cells that lack
of CEBPD may lose the ability to differentiate, arrest growth and
control the cell cycle, leading to tumor progression. Those data also
suggested that an optimal level of CEBPD is important in maintaining
the cellular function of liver cells.
The results of this study suggest that hepatic lipogenesis and viability
ability are controlled by the post-translational modiﬁcation of the
adipogenic transcription factor, CEBPD, and chromatin-modifying
enzymes, HDAC1 andHDAC3, for executingexternal-activation of cellular
response. They also reinforce the idea that the CEBPD may participate in
themodulation of lipogenesis aswell as the induction of growth arrest as
previously shown. This emphasizes the therapeutic potential of CEBPDby
regulating its expression in controllingpathological responses in the liver.
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